Robert Sebra is an Associate Professor of the Department of Genetics and Genomic Sciences and a member of the Icahn Institute of Data Science and Genomic Technology.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Sebra during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Employment:
- Sema4
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Sema4
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Nothing other than Section I; Sema4
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.